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Abstract
Background: Stress, anxiety and depression can cause complex physiological and neuroendocrine changes,
resulting in increased level of stress related hormone catecholamine, which may constitute a primary mechanism
by which physiological factors impact gene expression in tumors. In the present study, we investigated the effects
of catecholamine stimulation on MMP-7 expression in gastric cancer cells and elucidated the molecular
mechanisms of the up-regulation of MMP-7 level by catecholamine through an adrenergic signaling pathway.
Results: Increased MMP-7 expression was identified at both mRNA and protein levels in the gastric cancer cells in
response to isoproterenol stimulation. b2-AR antigonist effectively abrogated isoproterenol-induced MMP-7
expression. The activation of STAT3 and AP-1 was prominently induced by isoproterenol stimulation and AP-1
displayed a greater efficacy than STAT3 in isoproterenol-induced MMP-7 expression. Mutagenesis of three STAT3
binding sites in MMP-7 promoter failed to repress the transactivation of MMP-7 promoter and silencing STAT3
expression was not effective in preventing isoproterenol-induced MMP-7 expression. However, isoproterenol-
induced MMP-7 promoter activities were completely disappeared when the AP-1 site was mutated. STAT3 and
c-Jun could physically interact and bind to the AP-1 site, implicating that the interplay of both transcriptional
factors on the AP-1 site is responsible for isoproterenol-stimulated MMP-7 expression in gastric cancer cells. The
expression of MMP-7 in gastric cancer tissues was found to be at the site where b2-AR was overexpressed and the
levels of MMP-7 and b2-AR were the highest in the metastatic locus of gastric cancer.
Conclusions: Up-regulation of MMP-7 expression through b2-AR-mediated signaling pathway is involved in
invasion and metastasis of gastric cancer.
Background
Gastric cancer is the second most common leading cause
of cancer related death, with around 700 000 deaths each
year [1,2]. One of the important factors in the pathogen-
esis of gastric cancer is chronic infection with Helicobacter
pylori [3]. However, the majority of infected individuals do
not develop malignancy and the outcome of the infection
is dependent on host, environmental and other factors [4].
There is growing evidence supporting the role of psycho-
logical stress in the gastric cancer onset and development
[5]. Several epidemiological studies have demonstrated
that psychological or behavioral stress factors may acceler-
ate the progression of gastric cancer [6,7]. However, the
precise mechanism by which psychological stress acts in
gastric cancer progression is unclear.
Stress initiates a response of the hypothalamic-pitui-
tary-adrenal axis (HPA), resulting in increased catechola-
mine level [8,9]. Several studies have shown that the
stimulation of catecholamine interferes with bio-beha-
viors of tumor cells directly, mainly through b2-adrener-
gic receptors (b2-AR)-mediated signaling pathway
[10-14]. Recent observations pointing to a potential
mechanism for the progression of ovarian, nasopharyn-
geal and pancreatic cancers indicate that catecholamine
may modulate the expression of matrix metalloproteinase
(MMP)-2 and MMP-9 by stroma and tumor cells [15-17].
It raises an interesting question that psychological stress
m a yp l a yar o l ei nt h ed e v e l o p m e n ta n dp r o g r e s s i o no f
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through b2-AR mediated signaling pathway.
Accumulated lines of evidence show that MMP-7 is
involved in the invasion and metastases of gastric cancer
[18-24]. MMP-7 is the smallest known member of
MMP family and possesses the highest extracellular
matrix (ECM)-degradative activity against a variety of
ECM components, including elastin, gelatin, type IV col-
lagen, fibronectin, vitronectin, laminin, entactin, aggre-
can and proteoglycans, among the MMPs [25,26]. It is
also capable of triggering the activation of an MMP cas-
cade [27]. A unique feature of MMP-7 is its restricted
expression predominantly in epithelial cells of glandular
tissue including normal mammary, liver, pancreas, pros-
tate and peribronchial glands [28].
It has been found that MMP-7 is overexpressed in the
invasive cancers of digestive organs, such as oesophageal
[29], gastric [30], pancreatic [31,32], colorectal [33-35],
liver [36] and other organs. The expression level of
MMP-7 is significantly associated with the transforma-
tion of tumor cells, phenotypes of aggressive cancers
and stage of tumor progression [37], especially in
tumors of gastrointestinal tract. The overexpression of
MMP-7 is frequently identified in premalignant gastric
lesions and most gastric carcinomas [18-21,24,38].
A positive correlation of MMP-7 level with the tumor
invasion of the gastric wall, lymph node metastasis, peri-
toneal dissemination and survival of gastric cancer
patients has been documented in several studies [23].
MMP-7 has been recognized as an important mediator
of cancer progression and considered as an independent
prognostic marker for primary gastric cancer. However,
the possible molecular mechanisms of MMP-7 overex-
pression in gastric cancer are still largely unexplored.
In the present study, we investigated the effects of
catecholamine stimulation on MMP-7 expression in gas-
tric cancer cell lines and elucidated the molecular
mechanisms of the up-regulation of MMP-7 level by
catecholamine through an adrenergic signaling pathway.
Results
Isoproterenol stimulation up-regulates the expression of
MMP-7
It was shown that the expression of MMP-9 in ovarian
cancer was significantly enhanced in tumor associated
macrophages in the patients with elevated depressive
symptoms [15] and catecholamine potentiated LPS-
induced expression of MMPs in human monocytes [39].
In order to investigate whether catecholamine associates
with the expression of MMP-7 in gastric cancer cells,
we first inspected the effects of b-AR agonist isoprotere-
nol on the transcription of MMP-7 gene in gastric can-
cer cell lines HGC-27 and MGC-803. The doses of
catecholamine used in this study were selected to reflect
the physiologic conditions of this hormone in tumors
[40,41]. Semi-quantitative and real-time PCR analyses
showed that MMP-7 expression at transcriptional level
was low in gastric cancer cell lines. When the cells were
exposed to 10 μM of isoproterenol in the serum-free
media for 12 h, MMP-7 mRNA levels were remarkably
increased in both cell lines (Fig. 1A and 1B). To deter-
mine whether the increased level of MMP-7 mRNA
leads to a similar increase in the protein production,
MMP-7 expression in HGC-27 and MGC-803 cells was
analyzed by Western blot. As shown in Fig. 1C, isopro-
terenol stimulation resulted in a significant
up-regulation of MMP-7 expression in HGC-27 and
MGC-803 cells. b2-AR, which mediates most of the
effects of catecholamine, has been identified in breast
and ovarian cancer cells [11,13]. To clarify the role of
b2-AR-mediated signaling in MMP-7 expression, we uti-
lized a b-AR antagonist propranolol and selective b2-AR
antagonist ICI-118,551 to test if the effect of isoprotere-
nol on MMP-7 expression can be inhibited. Our data
showed that the treatment with propranolol and ICI-
118,551 efficiently blocked isoproterenol-stimulated
MMP-7 expression (Fig. 1D, upper panel). We then
examined whether b2-AR is expressed in gastric cancer
cells. The data showed that the expression of b2-AR
was detectable in three gastric cancer cell lines including
HGC-27, MGC-803 and MKN-45 (Fig. 1D, lower panel).
These data indicated that isoproterenol stimulated the
production of MMP-7 in gastric cancer cell lines and
that the up-regulation of MMP-7 expression by isopro-
terenol was mainly triggered by b2-AR mediated
signaling.
Isoproterenol up-regulates MMP-7 promoter activity and
activates STAT3 and AP-1
To explore the molecular mechanisms by which cate-
cholamine up-regulates MMP-7 expression, we first
determined if isoproterenol stimulation can directly
affect MMP-7 promoter activity. We constructed a
plasmid pMMP-7 containing a luciferase reporter gene
driven by a 340 bp MMP-7 promoter fragment (-296
- +44) (Fig. 2A). MGC-803 cells were transfected with
pMMP-7 and the effect of isoproterenol on MMP-7
promoter activity was assessed by luciferase assays. As
shown in Fig. 2B, after isoproterenol stimulation for 1 h,
the luciferase activities began to rise and gradually
enhanced. At 6 h after exposure, MMP-7 promoter
activities showed an over twofold increase compared
with the unstimulated control cells, suggesting that iso-
proterenol stimulation could directly induce the transac-
tivation of MMP-7 promoter.
In our previous study [42,43], we identified an AP-1
binding site at the position -67 to -61 and three STAT3
binding sites at the positions -137 to -122, -168 to -159
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demonstrated that AP-1 and STAT3 bound to AP-1 and
one of the STAT3 (-137 to -122) sites, positively regulating
MMP-7 transcription. A recent study showed that
catecholamine has the potential to activate STAT3. To
investigate whether catecholamine stimulates MMP-7
transcription via the activation of STAT3 and AP-1, we
analyzed the phosphorylation of STAT3 and c-Jun. Fig. 2C
showed that isoproterenol caused the phosphorylation of
STAT3 after 30 min stimulation, reaching a peak at 2 h.
Although the activation of c-Jun was slow, initiated at 60
min, a maximum phosphorylation was achieved at 2 h as
well (Fig. 2D). It signified that isoproterenol stimulation
produced a b2-AR-mediated signal that triggered the acti-
vation of STAT3 and AP-1.
STAT3 element in MMP-7 promoter is not required and
STAT3 not sufficient for isoproterenol-induced MMP-7
expression
In order to determine whether the STAT3 elements are
functional in isoproterenol-induced MMP-7 gene tran-
scription, we first undertook the mutagenesis of three
STAT3 sites through mutating the core-sequences of
S T A T 3s i t e sb a s e do np M M P - 7( F i g .3 A )a n dc o n -
structed the plasmid pMMP-7mS. The plasmid was
transfected into MGC-803 cells. After transfection for
Figure 1 Isoproterenol stimulation up-regulates the expression of MMP-7. A and B, HGC-27 and MGC-803 cells were incubated overnight
in serum-free medium and then treated with 2 or 10 μM isoproterenol, respectively. The expression of MMP-7 mRNA was analyzed by RT-PCR
(A) and real-time PCR (B). C, HGC-27 cells were stimulated with 0, 1 or 2 μM isoproterenol and MGC-803 cells with 0, 5 and 10 μM isoproterenol
after serum starvation. The expression of MMP-7 protein was analyzed by Western blot. D, MGC-803 cells were treated with 10 μM propranolol
or 1 μM ICI-118,551 for 1 h and then with 10 μM isoproterenol. MMP-7 expression was analyzed by Western blot (upper panel); the expression
of b2-AR in MGC-803, MKN-45 and HGC-27 cells was detected by Western blot (lower panel).
Shi et al. Molecular Cancer 2010, 9:269
http://www.molecular-cancer.com/content/9/1/269
Page 3 of 1448 h, the cells were incubated in serum-free medium
overnight and then stimulated with 10 μM of isoprotere-
nol for 6 h. We noticed, surprisingly, that the mutation
of all three STAT3 binding sites had no prominent
effect on the transactivation of MMP-7 promoter. As
shown in Fig. 3B, luciferase activities were gradually
increased and approached a peak at 6 h after exposure.
The result was very similar to that observed in the cells
transfected with wild type MMP-7 promoter. To identify
the role of STAT3 in this event, HGC-27 and MGC-803
cells were transfected with pGeneSuppressor expressing
shRNA targeting STAT3 and HGC-27/STAT3-sh and
MGC-803/STAT3-sh cells established. Fig. 3C showed
that the expression of STAT3 was efficiently suppressed
in both cells. Consistent with above data, isoproterenol-
induced MMP-7 promoter activities appeared not to be
significantly impaired in MGC-803/STAT3-sh cells (Fig.
3D). Furthermore, isoproterenol-induced MMP-7
expression at both mRNA and protein levels was not
importantly affected by silencing STAT3 expression as
demonstrated by RT-PCR, real-time PCR and Western
blot (Fig. 3E, F and 3G). The results suggested that
STAT3 element in MMP-7 promoter is not required
a n dS T A T 3n o ts u f f i c i e n tf o ri s o p r o t e r e n o l - i n d u c e d
MMP-7 expression.
AP-1 plays a critical role in isoproterenol-induced MMP-7
expression
The above data was unexpected, since STAT3 could be
activated by isoproterenol stimulation. In addition, in
our previous study [42,43], we demonstrated that
STAT3 and AP-1 participated in regulating Her2 signal-
ing-mediated MMP-7 expression in breast cancer cells.
We then sought to investigate whether AP-1 influences
Figure 2 Isoproterenol up-regulates MMP-7 promoter activity and activates STAT3 and AP-1. A, schematic representation of the plasmid
pMMP-7 containing a luciferase reporter gene driven by a 340 bp MMP-7 promoter fragment. SBE, STAT3 site; ABE, AP-1 site. B, MGC-803 cells
were co-transfected with pMMP-7 and pRL-TK. After transfection for 48 h, the cells were incubated in serum-free medium for an additional 24 h
and then stimulated with 10 μM isoproterenol for 0, 1, 2, 3, 6 or 9 h, respectively. MMP-7 promoter activities were assessed by luciferase assays.
C and D, MGC-803 cells were treated with 10 μM propranolol for 1 h and then with 10 μM isoproterenol for 0, 15, 30, 60, 120 or 180 min,
respectively. The phosphorylation of STAT3 and c-Jun was analyzed by Western blot with anti-phosphor-STAT3 and anti-phosphor-c-Jun rabbit
polyclonal antibodies. ISO, isoproterenol.
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cells were transfected with the plasmid pMMP-7mA
containing a mutated AP-1 site at the position -67 to
-61 in MMP-7 promoter and luciferase activities mea-
sured (Fig. 4A). Surprisingly, isoproterenol-induced
MMP-7 promoter activities were completely disappeared
at all time points (Fig. 4B), suggesting that the AP-1 site
was crucial in isoproterenol-induced MMP-7 expression.
To confirm isoproterenol-induced MMP-7 expression
is controlled by AP-1, we then examined whether the
transactivation of MMP-7 promoter induced by isopro-
terenol could be inhibited by a dominant negative c-Jun
Figure 3 STAT3 element in MMP-7 promoter is not required and STAT3 not sufficient for isoproterenol-induced MMP-7 expression.
A, schematic representation of the plasmid pMMP-7mS containing three mutated STAT3 sites at the positions -255 to -245, -168 to -159 and
-137 to -122. B, MGC-803 cells were co-transfected with pMMP-7mS and pRL-TK, starved, and then stimulated with 10 μM isoproterenol for 0, 1,
2, 3, 6 or 9 h, respectively. MMP-7 promoter activities were assessed by luciferase assays. C, HGC-27 and MGC-803 cells were stably transfected
with pGeneSuppressor expressing STAT3 shRNA. The expression of STAT3 was analyzed by Western blot in HGC-27/STAT3-sh and MGC-803/
STAT3-sh cells. D, MMP-7 promoter activities were assayed in MGC-803/STAT3-sh cells after stimulation with 10 μM isoproterenol for 0, 1, 2, 3, 6
or 9 h, respectively. E through G, HGC-27/STAT3-sh and MGC-803/STAT3-sh cells were stimulated with 2 μMo r1 0μM isoproterenol, respectively.
The expression of MMP-7 was analyzed by RT-PCR (E), real-time PCR (F) and Western blot (G).
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Page 5 of 14Figure 4 AP-1 plays a critical role in isoproterenol-induced MMP-7 expression. A, schematic representation of the plasmid pMMP-7mA
containing a mutated AP-1 site at the position -67 to -61. B, MGC-803 cells were co-transfected with pMMP-7mA and pRL-TK, starved and then
stimulated with 10 μM isoproterenol for 0, 1, 2, 3, 6 or 9 h, respectively. MMP-7 promoter activities were assessed by luciferase assays. C, MGC-
803 cells co-transfected with TAM67, pMMP-7 and pRL-TK were induced with 10 μM isoproterenol. MMP-7 promoter activities were analyzed by
luciferase assays. D, MGC-803 cells stably expressing shRNA targeting c-Jun (MGC-803/c-Jun-sh) were established and c-Jun expression was
analyzed by Western blot. E, MMP-7 promoter activities were assayed in MGC-803/c-Jun-sh cells after stimulation with 10 μM isoproterenol for 0,
1, 2, 3, 6 or 9 h, respectively. F, MMP-7 expression was analyzed in MGC-803/c-Jun-sh cells after stimulation with 0, 2 or 10 μM isoproterenol,
respectively. G, the plasmids expressing c-Jun and STAT3C were transfected into MGC-803/c-Jun-sh cells, respectively. MMP-7 promoter activities
were analyzed by luciferase assays.
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domain but possesses a functional c-Jun leucine zipper
and DNA-binding domain. After transient transfection
with TAM67 into MGC-803 cells, isoproterenol-induced
transactivation of MMP-7 promoter was analyzed by
luciferase assays. As shown in Fig. 4C, the expression of
the dominant negative c-Jun exhibited a conspicuous
dampening impact on MMP-7 promoter activities. To
further verify the critical role of AP-1, we tested
whether blocking endogenously expressed c-Jun can
inhibit the expression of MMP-7. The MGC-803/c-Jun-
shcells were established (Fig. 4D) and MMP-7 promoter
activities analyzed by luciferase assays. The data in Fig.
4E showed that the activities of MMP-7 promoter were
strikingly reduced by knock-down of c-Jun expression.
Western blot analysis also demonstrated that isoproter-
eol-induced MMP-7 expression was markedly decreased
in MGC-803/c-Jun-sh cells, whereas a substantially large
amount of MMP-7 protein was detected in the parental
cells after isoproterenol stimulation (Fig. 4F). Notably,
the overexpression of exogenous c-Jun dramatically
restored MMP-7 promoter activities in MGC-803/c-Jun-
sh cells, but constitutively activated STAT3 mutant
STAT3C only minimally activated MMP-7 promoter
when c-Jun expression was silenced (Fig. 4G). These
data proved that AP-1 dominated isoproterenol-induced
MMP-7 expression.
c-Jun and STAT3 synergistically regulate MMP-7
expression in response to isoproterenol stimulation
Cooperation of Stat3 and c-Jun in regulating a variety of
gene transcription has been reported. Our previous
study demonstrates that the activation of MMP-9 pro-
moter is dependent upon the interaction of Stat3 and
AP-1 [44]. As mentioned above, isoproterenol stimula-
tion induced the activation of STAT3 and AP-1 simulta-
neously. We speculated that Stat3 and AP-1 may
synergistically participate in the regulation of isoprotere-
nol-stimulated MMP-7 expression. It has been indicated
that AP-1 cooperates with STAT3 in interleukin 6-
induced transactivation of the IL-6 response element in
the absence of direct AP-1 DNA binding [45]. It
prompted us to test the possible cooperative binding of
AP-1/STAT3 to the AP-1 site.
To determine whether that STAT3 and AP-1 can be
recruited to the AP-1 site in MMP-7 promoter in vivo,
MGC-803 cells were stimulated with 10 μMo fi s o p r o -
terenol for 0, 2.5 or 4 h, respectively. The chromatin
DNA/nuclear protein complexes were prepared and
binding of STAT3 and c-Jun to the AP-1 site was ana-
lyzed by ChIP assays. The PCR product selected for
amplification extends from the -76 to +165 region har-
boring the AP-1 site in MMP-7 promoter. The immu-
noprecipitation with anti-STAT3 and anti-c-Jun
antibodies followed by PCR yielded an expected 241 bp
band from the precipitants after isoproterenol stimula-
tion for 2.5 h. The intensities of these bands were wea-
kened after 4 h. In contrast, in unstimulated control
cells no binding of STAT3 to this site was observed and
the binding of c-Jun barely detectable. No band was
amplified by immunoprecipitation using rabbit IgG
(Fig. 5A). The data were confirmed by real-time PCR
(Fig. 5B). These data demonstrated that the association
of STAT3 and c-Jun with MMP-7 promoter in vivo was
specific and that isoproterenol stimulation induced bind-
ing of STAT3/c-Jun to the AP-1 element.
To further characterize the interaction of STAT3/c-
Jun with the AP-1 site, we performed a DNA affinity
precipitation assay. After MGC-803 cells were treated
with isoproterenol for 2.5 h, the nuclear extract was pre-
pared and its quality was assessed (Fig. 5C). The biotiny-
lated oligonucleotides corresponding to -74 to -52
region of MMP-7 promoter were incubated with 200 μg
of the nuclear extracts for the pull-down assays. The
streptavidin coated magnetic beads were used to precipi-
tate biotin-labeled double-stranded oligonucleotides and
associated DNA binding proteins. The binding of the
nuclear proteins to the biotinylated oligonucleotides was
analyzed in the presence of one, five, or 15 fold amount
of double-stranded oligonucleotide competitors contain-
ing AP-1 consensus sequences. Incubation of the
nuclear proteins with the double-stranded oligonucleo-
tides containing a mutated AP-1 site or non-specific
double-stranded oligonucleotides was used as controls.
The resulting DNA-protein complexes were resolved by
SDS-PAGE, followed by Western blot with anti-c-Jun
and anti-STAT3 antibodies. The association of both
transcriptional factors with the oligonucleotides contain-
ing AP-1 consensus sequences could be clearly detected
in the nuclear extracts from isoproterenol-stimulated
cells, but not from unstimulated cells. Competition with
fifteen fold amount of the competitors utterly abolished
the formation of the biotinylated DNA/protein com-
p l e x e s( F i g .5 D ) .N ob i n d i n go fc - J u na n dS T A T 3t o
either the oligonucleotides containing a mutated AP-1
site or nonspecific oligonucleotides was detected (Fig.
5D). This experiment provides in vitro evidence to con-
firm that STAT3 and c-Jun, under catecholamine stimu-
lation, can physically interact and bind to the AP-1 site
to achieve transactivation of MMP-7 gene in gastric
cancer cells.
We showed that isoproterenol-induced MMP-7 pro-
moter activation was not disrupted by the mutagenesis
of the core-sequences of all three STAT3 sites, suggest-
ing that the STAT3 elements may not act in isoprotere-
nol-induced MMP-7 gene transcription in gastric cancer
cells. To further verify the role of AP-1 element, the
plasmid pMMP-7mA was co-transfected into MGC-803
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Page 7 of 14Figure 5 c-Jun and STAT3 synergistically regulate MMP-7 expression. A and B, MGC-803 cells were stimulated with 10 μM of isoproterenol
for 0, 2.5 or 4 h, respectively. The chromatin DNA/nuclear protein complexes were prepared. Binding of STAT3 and c-Jun to the AP-1 site was
analyzed by the immunoprecipitation with anti-STAT3 and anti-AP-1 antibodies followed by PCR (A) and real-time PCR (B). C, MGC-803 cells were
treated with 10 μM isoproterenol for 0 or 2.5 h, respectively. The nuclear extract was prepared with a Nuclear-Cytosol Extraction Kit. b-tubulin
and AP-2a were analyzed by Western blot to examine the separation of cytoplasmic and nuclear proteins. C, cytosolic proteins; N, nuclear
proteins. D, 200 μg of the nuclear extracts was incubated at 4°C for 4 h with the biotinylated oligonucleotides containing AP-1 consensus
sequence previously coupled to Dynabeads M-280 in the presence or absence of one, five or 15 fold amount of the double-stranded
oligonucleotide competitors. Incubation of the nuclear proteins with the double-stranded oligonucleotides containing a mutated AP-1 site (Mut
Oligo) or non-specific double-stranded oligonucleotides (NS Oligo) was used as controls. The protein/DNA complexes were separated with a
Dynal magnet, and subjected to SDS-PAGE. STAT3 and c-Jun were detected by Western blot with anti-STAT3 and anti-c-Jun antibodies. E and F,
MGC-803 cells were co-transfected with the plasmids pMMP-7mA and pCDNA3.1/c-Jun or STAT3C and luciferase activities were assayed.
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tively. Interestingly, the mutation of AP-1 binding site
thoroughly blocked the activation of MMP-7 promoter
in the transfected cells overexpressing either c-Jun or
STAT3C (Fig. 5E and 5F), indicating that the AP-1 site
is an important regulatory element and the synergistic
regulation of isoproterenol-induced MMP-7 expression
by STAT3 and AP-1 relies on this element.
b2-AR and MMP-7 were colocalized in gastric cancer
tissues
The overexpression of MMP-7 was frequently at the
invasive front of human gastric cancer and directly asso-
ciated with prognosis in patients with gastric cancer. To
study the correlation of b2-AR level with MMP-7
expression in human gastric cancer, we collected five
gastric cancer tissue samples and analyzed the expres-
sion of b2-AR and MMP-7 by immunohistochemical
labeling. Interestingly, the strong expression of b2-AR
and MMP-7 emerged at the same region of the tumor
tissues (Fig. 6A), suggesting an intimate relationship
between MMP-7 and b2-AR. To further investigate the
role of MMP-7 and b2-AR in the metastasis of gastric
cancer, we analyzed the expression MMP-7 and b-ARs
in the cancerous, peri-cancerous and metastatic tissues
from a patient with gastric cancer. As shown in Fig. 6B,
the expression of b1-AR, b2-AR and MMP-7 at protein
level was higher in cancerous tissue than in peri-cancer-
ous tissue. However, the highest expression of them was
found in the metastatic tissue. Moreover, MMP-7
Figure 6 b2-AR and MMP-7 were overexpressed in gastric cancer tissues.A ,f i v eg a s t r i cc a n c e rt i s s u es a m p l e sw e r ec o l l e c t e d .T h e
expression of b2-AR and MMP-7 was analyzed by immunohistochemistry. B, the expression of MMP-7, b1-AR and b2-AR in the cancerous, peri-
cancerous and metastatic tissues was analyzed by Western blot. C, the level of MMP-7 mRNA in the cancerous, peri-cancerous and metastatic
tissues was analyzed by real-time PCR.
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(Fig. 6C). These data strongly imply a close link among
MMP-7, b2-AR and metastasis of gastric cancer.
Discussion
The present study was based on the hypothesis that psy-
chosocial stress may be a predisposing factor in gastric
cancer. Stress, anxiety and depression can cause com-
plex physiological and neuroendocrine changes that
influence multiple systems, including the digestive sys-
tem. The cancer patients often experience substantial
emotional distress. The association of physiological
stress with elevation of gastric acid secretion and stoma-
chache has long been noticed [46,47]. It has been
reported that chronic stress can aggravate stomach
ulcers. In a recent population-based survey enrolled
2014 subjects, stress was regarded as the most powerful
risk factor in gastric cancer [48]. The findings from
experimental studies suggest that increased activity of
the sympathetic nervous system may constitute a pri-
mary mechanism by which physiological factors impact
gene expression in tumors [49]. To date, most studies
investigating the mechanisms connecting stress and can-
cer progression has been related to indirect effects
through the immunosuppression [8]. In several recent
studies, stress related proteins and pathways were linked
directly to the behavioral alteration of malignant cells
[10-17]. However, there is a paucity of data delineating
the molecular mechanisms involved.
In the present study, we identified increased MMP-7
expression in the gastric cancer cell lines in response to
the stimulation of stress-related hormone catecholamine.
It is estimated that the concentration of catecholamine
could be over 100 times higher in the tumor microen-
vironment than in normal tissues and circulating
plasma. MMP-7 is unique in its restricted expression in
tumor cells, indicating that MMP-7 expression is in a
tumor-associated fashion. We noticed that isoproterenol
stimulation significantly up-regulated MMP-7 expression
at both mRNA and protein levels in gastric cancer cells.
b2-AR antigonist effectively abrogated isoproterenol-
induced MMP-7 expression up-regulation, suggesting
that b2-AR-mediated pathway is involved in the process.
MMP-7 expression is tightly controlled at the level of
transcription. Our previous study demonstrated that
heregulin-b-induced MMP-7 expression was regulated
by HER2-mediated STAT3 and AP-1 activation in
human breast cancer cell lines [42,43]. We also identi-
fied the functional AP-1 and STAT3 binding sites in the
first 350 bp of the transcription start site in human
MMP-7 promoter [42,43]. Another study indicated that
FGF-2 could directly upregulate MMP-7 gene expres-
sion in human tumor cell lines and umbilical vein
endothelial cells through AP-1 and STAT3 [50].
Accumulating evidence strongly supports that STAT3
serves as a central regulatory node on which multiple
oncogenic signaling pathways converge [51]. Aberrant
activation of STAT3 has been proved to play a critical
role in gastric cancer development [52,53]. A recent
study and our data uncovered the association of cata-
cholamine with STAT3 activation in ovarian and breast
cancer cells [12,13]. In the present study, we demon-
s t r a t e dt h a ti s o p r o t e r e n o lstimulation prominently
induced the activation of STAT3 in gastric cancer cells,
implicating that catecholamine may accelerate the
malignant progression of gastric cancer. Our unpub-
lished data also proved that isoproterenol stimulated the
expression of MMP-2 and MMP-9 in gastric cancer
cells mainly through activating STAT3. However, in this
study, we found that AP-1 displayed a greater efficacy
than STAT3 in isoproterenol-induced MMP-7 gene
transcription and the STAT3 elements were non-func-
tional, as silencing STAT3 expression was not effective
in preventing isoproterenol-induced MMP-7 expression
and mutagenesis of three STAT3 binding sites failed to
repress the transactivation of MMP-7 promoter in
response to isoproterenol induction. In contrast, the
AP-1 site and c-Jun governed this process. Interestingly,
STAT3 and c-Jun were found to bind to the single AP-1
site in MMP-7 promoter simultaneously, implicating
that the interplay of both transcriptional factors at one
binding site is responsible for isoproterenol-stimulated
MMP-7 expression in gastric cancer cells. We have
demonstrated that STAT3 and AP-1 are important tran-
scriptional regulators of MMP-7 and MMP-9 in human
breast cancer cells previously and STAT3 and AP-1
exert transcriptional regulation functions by binding to
their respective elements [42-44]. Given the results of
these data, catecholamine-induced MMP-7 expression
may be primarily in a cell type specific manner.
Several lines of evidence indicate that the expression
of MMP-7 is associated with advanced clinicopathologi-
cal stages and unfavorable prognosis in gastric cancer
[18-24,38,54]. Recent studies showed that MMP-7
expression was selectively up-regulated by pathogenic
strains of Helicobacter pylori in Helicobacter pylori gas-
tritis [20], which is considered as the initial stage in the
progression to gastric carcinoma. MMP-7 is also identi-
fied as a target of gastrin in hypergastrinemia that is
associated with gastric cancer [38]. These data suggest
that MMP-7 is an important mediator in gastric cancer
development. MMP-7 affects the gastric microenviron-
ment by degrading ECM components. It also plays a key
role in the activation, degradation, release and shedding
of cell-surface molecules, such as pro-heparin-binding
epidermal growth factor, Fas ligand, a stimulator of the
death receptor FAS, cell adhesion molecule E-cadherin
and insulin-like growth factor binding protein, thus
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and promoting tissue invasion and metastasis [37]. We
noticed that the overexpression of MMP-7 emerged at
the region where b2-AR was expressed highly and the
level of MMP-7 and b2-AR is the highest in the meta-
static locus of gastric cancer, suggesting a direct role of
b2-AR-mediated MMP-7 expression in the invasion and
metastasis of gastric cancer, and also implying an impor-
tant effect of neuroendocrine “macroenvironment” on
the gastric tumor microenvironment.
Conclusions
T h em a i nf i n d i n g so ft h i ss t u d ys t r o n g l ys u p p o r tt h e
hypothesis that up-regulation of MMP-7 expression
through b2-AR-mediated signaling pathway is involved
in invasion and metastasis of gastric cancer. b2-AR may
serve as a target of therapeutic intervention. An under-
standing of how MMP-7 gene is up-regulated under
stress will help to elucidate the mechanisms of MMP-7
overexpression in gastric cancer, especially at an early
stage. Further identification of the down-stream effector
molecules of b2-AR cascades will not only provide a
more definite knowledge of the signaling network in
response to catecholamine stimulation, but also close an
important gap linking psychosocial stress and the cellu-
lar consequences in gastric cancer.
Methods
Cell culture and treatment
Human gastric cancer cell lines HGC-27 and MGC-803
(the American Type Culture Collection) were incubated
in Dulbecco’s modified Eagle’s medium (DMEM) (Invi-
trogen) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen) at 37°C in a humidified atmosphere
of 5% CO2. For the treatment with b-AR agonists, the
cells were incubated overnight in serum-free medium
supplemented with 0.1% BSA, 10 mM HEPES (pH 7.4)
prior to stimulation. Then HGC-27 cells were treated
with 0, 1, or 2 μM isoproterenol (Sigma) and MGC-803
cells 1, 5, or 10 μM isoproterenol for indicated time
points. For b-AR antagonist treatment, the cells were
first treated with 10 μM propranolol (TOCRIS) or 1 μM
ICI-118,551 (TOCRIS) for 1 h before AR agonist
stimulation.
Constructs
The promoter region (nucleotides -296 to +44 relative
to the ATG initiation codon) of human MMP-7 gene
was PCR amplified from MGC-803 cell genomic DNA
using the primers P1 and P2 (Table 1) with Power Pfu
DNA polymerase (BioTeke) and inserted into the Kpn I
and Hind III sites immediately upstream of a firefly luci-
ferase gene in pGL3-Basic reporter vector (Promega)
designated pMMP-7. Using pMMP-7 as a templet, two
mutated MMP-7 promoter fragments were generated by
PCR with the primers P1 - P7 or P1, P2, P8 and P9
(Table 1), respectively, and cloned into the plasmid
pGL3-Basic. The resultant recombinant plasmids were
named pMMP-7mS containing three mutated STAT3
sites at the positions -255 to -245, -168 to -159, and
-137 to -122 and pMMP-7mA harboring a mutated AP-
1 site at the position -67 to -61. All expression con-
structs were verified by sequence analysis. The plasmid
pRc/CMV-Stat3C-Flag (constitutive activated Stat3,
Stat3C) and STAT3 dominant negative construct
(STAT3-YF) are generous gifts from Drs. Bromberg and
Darnell. The plasmid pCDNA3.1/c-Jun was constructed
in our previous study [55]. The plasmid pRL-TK (Pro-
mega) was used as a control plasmid. The sequences 5’-
GCAGCAGCTGAACAACATGTC-3’ in STAT3 mRNA
and 5’-AACAGGTGGCACAGCTTAAAC-3’ in c-Jun
mRNA were selected through the siRNA Target Finder
(http://www.ambion.com/techlib/misc/siRNA_finder.
html, Ambion) as siRNA target sites. The synthetic dou-
ble-strand oligonucleotides (sense: 5’-TCGAGCAGCAG
CTGAACAACATGTCGGAATTCGGACATGTTGTTC
AGCTGCTGCTTTTT-3’ and antisense: 5’-CTAGAAAA
AGCAGCAGCTGAACAACATGTCCGAATTCCGAC
ATGTTGTTCAGCTGCTGC-3’ for STAT3 and sense:
5’-TCGAAACAGGTGGCACAGCTTAAACGGAATT
CGGTTTAAGCTGTGCCACCTGTTTTTTT-3’ and
antisense: 5’-CTAGAAAAAAACAGGTGGCACAGCTT
AAACCGAATTCCGTTTAAGCTGTGCCACCTGTT-3’
for c-Jun) were inserted into pSuppressorNeo plasmid
(Imgenex) according to the manufacturer’s recommen-
dation. The plasmid containing the corresponding
scrambled target sequences was used as a control.
Table 1 The primers used
No. Sequences
P1 5’-CGGGGTACCATAATGTCCTGAATGATACC-3’
P2 5’-CCCAAGCTTTGCCGTCCAGAGACAATTG-3’
P3 5’-CGGGGTACCATAATGTCCTGAATGATACCTAT
GAGAGCAGTCATTTGACGCTGGCAAAA-3’
P4 5’-CATTGTGTGCTCCCTGCCACTAACGATGTAATACTT-3’
P5 5’-TTGTCTTTCAAAGGATT-3’
P6 5’-TACTTCCTCGTCCTAGCCAATGCAAAATAACACATAC-3’
P7 5’ - GTTATTGGCAGGAAGCACAC - 3’
P8 5’-GAAAACACTCAAACGAGTGACCTATTTCCACAT-3’
P9 5’-TTTCTTTTTAGAGTCTACAG-3’
P10 5’-GAGTGCCAGATGTTGCAGAA-3’
P11 5’-GTGAGCATCTCCTCCGAGAC-3’
P12 5’-GTGGGGCGCCCCAGGCACCA-3’
P13 5’-CTTCCTTAATGTCACGCACGATTTC-3’
P14 5’-ACACATACTTTCAAAGTTCTGTAGACTCT-3’
P15 5’-ACGGTGAGTCGCATAGCT-3’
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Cells were co-transfected with pMMP-7 or pMMP-7mS
or pMMP-7mA and pRL-TK reporter plasmid contain-
ing the Renilla luciferase reporter gene using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
protocol. After transfection for 48 h, the cells were incu-
bated in serum-free medium for an additional 24 h and
then stimulated with 10 μM isoproterenol for indicated
time points. For luciferase assays, cells were lysed in
lysis buffer (Promega). Firefly and Renilla luciferase
activities were measured with a dual luciferase assay kit
(Promega) according to the manufacturer’s instructions.
All transfections were carried out in triplicate and
repeated at least three times.
Western blot
The whole cell lysates were prepared, separated by SDS-
PAGE and transferred to PVDF membranes. After
blocking, blots were probed with the appropriate pri-
mary antibodies overnight at 4°C. The antibodies used
include anti-b2-AR rabbit polyclonal antibody (Santa
Cruz Biotechnology Inc.), anti-MMP-7 mouse monoclo-
nal antibody (Santa Cruz Biotechnology Inc.), anti-
STAT3 rabbit polyclonal antibody (Cell Signaling
Technology Inc.), anti-phosphor-STAT3 (Tyr705) rabbit
polyclonal antibody (Cell Signaling Technology Inc.),
anti-phosphor-c-Jun (Ser73) rabbit polyclonal antibody
(Cell Signaling Technology Inc.), anti-b2-AR rabbit
polyclonal antibody (Santa Cruz Biotechnology Inc.),
and anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) rabbit monoclonal antibody (Cell Signaling
Technology Inc.). The blots were then washed and incu-
bated with horseradish peroxidase-conjugated secondary
antibodies. Bands were detected by enhanced chemilu-
minesence (Pierce).
Conventional and real-time RT-PCR
For the examination of MMP-7 transcription induced by
catecholamine, HGC-27 and MGC-803 cells were trea-
ted with 2 or 10 μM of isoproterenol for 12 h. Then,
total RNA was isolated from HGC-27 and MGC-803
cells using TRIzol reagent (Invitrogen) following the
manufacturer’s instructions and quantified by spectro-
photometry. cDNA was synthesized by reverse transcrip-
tion kit (BioTeke) in accordance with the manufacturer’s
instructions and amplified by PCR with the specific pri-
mers P10 and P11 (Table 1) to screen the mRNA
expression of MMP-7. The PCR products were electro-
phoresed on 1.0% agarose gel. Amplification of b-actin
gene using the specific primers P12 and P13 (Table 1)
was used as an internal control. Real-time PCR was per-
formed using SYBR Green Supermix (TransGen Bio-
tech) on Real-Time PCR Detection System (Eppendorf)
as recommended by the manufacturer. The results were
analyzed using the comparative threshold cycle method
with b-actin as an internal control.
Immunohistochemistry
Paraffin-embedded tissues were cut (~5 μm). The sec-
tions were dewaxed in xylene, and gradually hydrated in
a decreasing ethanol series ending in distilled water.
Endogenous peroxidase activity was quenched using 3%
hydrogen peroxide in distilled water and then washed in
phosphate-buffered saline (PBS). After antigen retrieval,
the sections were incubated with anti-MMP-7 (Santa
Cruz Biotechnology Inc.) and anti-b2-AR (Abcam) rab-
bit polyclonal antibodies. Following washing with PBS,
the sections were subsequently incubated with horserad-
ish peroxidase-conjugated anti-rabbit antibody (Gene
Tech Biotechnology Co.). The color was developed by
incubation with 3, 3’-diaminobenzidine solution. The
sections were then counterstained with hematoxylin,
dehydrated, and mounted. Omission of the primary anti-
body and substitution by non-specific rabbit IgG at the
same concentration were used as negative controls.
Chromatin immunoprecipitation (ChIP)
MGC-803 cells were treated with 10 μMo fi s o p r o t e r e -
nol for 0, 2.5 and 4 h under serum-free conditions after
overnight starvation. The chromatin DNA of the cells
was prepared and ChIP assay performed by using the
SimpleChIPTM Enzymatic Chromatin IP Kit (Cell Sig-
naling Technology Inc.) following the protocol supplied
by the manufacturer. STAT3, c-Jun, and DNA com-
plexes were precipitated either by anti-STAT3 antibody
and anti-c-Jun antibody or by rabbit IgG as the negative
control. Precipitated DNA was amplified by PCR with
the primers P14 and P15 (Table 1) flanking AP-1 bind-
ing site (-67 to -61) in MMP-7 promoter. Final products
were resolved on a 1% agarose gel.
Preparation of nuclear extracts and oligonucleotide pull-
down assays
The 5’-biotinylated double-stranded oligonucleotides (5’-
ACTCAAATGAGTCACCTATTTCC-3’ and 5’-GGAAAT
AGGTGACTCATTTGAGT-3’) corresponding to the
positions -74 to -52 of MMP-7 promoter harboring AP-1
motif were synthesized by Invitrogen Biotechnology. The
same double-stranded sequences that are not biotinylated
were used as the competitors. The biotinylated oligo-
nucleotides containing the mutated AP-1 binding site
(5’-ACTCAAACGAGTGACCTATTTCC-3’ and 5’-GGA
AATAGGTCACTCGTTTGAGT-3’), in which conserved
nucleotides of AP-1 consensus sequence were replaced,
and the biotinylated oligonucleotides (5’-ACCAATGCA
GCCCTACCTGTAGC-3’ and 5’-GCTACAGGTAGGG
CTGCATTGGT-3’) corresponding to the positions -908
to -885 of MMP-7 promoter lacking the AP-1 binding site
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μM of isoproterenol for 0 or 2.5 h under serum-free con-
ditions after overnight starvation. The nuclear extracts
were prepared by using a Nuclear-Cytosol Extraction Kit
(Applygen Technologies) according to the manufacturer’s
instructions. 200 μg of the nuclear extracts was incubated
at 4°C for 4 h with each pair of the oligonucleotides pre-
viously coupled to Dynabeads M-280 (Invitrogen). The
protein/DNA complexes were separated with a Dynal
magnet, denatured in SDS sample buffer and subjected to
SDS-PAGE. STAT3 and c-Jun were detected by Western
blot with anti-STAT3 and anti-cJun antibodies.
Clinical samples
All clinical tissue samples were obtained from General
Hospital of PLA with the informed consent of patients
and with approval for experiments from General Hospi-
tal of PLA. The peri-cancerous, cancerous and perito-
neal metastatic tissues samples were obtained from a
patient (male, 62 years old) diagnosed as advanced gas-
tric cancer during radical subtotal gastrectomy.
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